PDPHF (Egetis Therapeutics AB) Long-Term Debt: $4.07 Mil (As of Mar. 2026)


PDPHF Egetis Therapeutics AB PDPHF
24 GF Score
Price $0.64
GF Value $0.64
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Long-Term Debt?

Egetis Therapeutics AB PDPHF 24 Long-Term Debt is $4.07 Mil as of Mar. 2026. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review.

Egetis Therapeutics AB's Long-Term Debt for the quarter that ended in Mar. 2026 was $4.07 Mil.

Egetis Therapeutics AB's quarterly Long-Term Debt declined from Sep. 2025 ($5.79 Mil) to Dec. 2025 ($4.84 Mil) and declined from Dec. 2025 ($4.84 Mil) to Mar. 2026 ($4.07 Mil).

Egetis Therapeutics AB's annual Long-Term Debt declined from Dec. 2023 ($10.08 Mil) to Dec. 2024 ($7.66 Mil) and declined from Dec. 2024 ($7.66 Mil) to Dec. 2025 ($4.84 Mil).

Egetis Therapeutics AB  (OTCPK:PDPHF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Egetis Therapeutics AB Long-Term Debt Related Terms

Egetis Therapeutics AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Long-Term Debt Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 10.08 7.66 4.84

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.86 6.16 5.79 4.84 4.07
PDPHF
24GF Score
Egetis Therapeutics AB PDPHF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $4.07 Mil mean?
Egetis Therapeutics AB (PDPHF) has a Long-Term Debt of $4.07 Mil as of Mar. 2026.
Is Egetis Therapeutics AB's Long-Term Debt too high?
Egetis Therapeutics AB's current Long-Term Debt is $4.07 Mil. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Long-Term Debt compare to VRTX and REGN?
Egetis Therapeutics AB's Long-Term Debt of $4.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Egetis Therapeutics AB's current Long-Term Debt is $4.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Long-Term Debt is $4.07 Mil. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Long-Term Debt is $4.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued. The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for PDPHF:

  • Long-Term Debt: $4.07 Mil
  • GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score

Get the complete analysis for PDPHF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.64
GF Value